Select Page

The return on my Jubak Picks Portfolio
from May 1997 through the end of 2014: 445%
ArrowCircle100

Jubak Picks Portfolio

Top Stocks for a 12-18 Month Horizon

Jubak Picks Performance Since 2007:
445%

NASDAQ
5861.9
+16.59
+0.28%
 
S&P500
2369.75
+2.41
+0.10%
 
NYSE
11558.35
+17.06
+0.15%
 
ACAD
39.85
+0.97
+2.49%
 
AGN
246.25
+0.88
+0.36%
 
ALV
105.02
+0.41
+0.39%
 
BABA
103.6
+0.65
+0.63%
 
BMY
56.56
+0.12
+0.21%
 
DHR
86.13
+0.05
+0.06%
 
DXJR
13.62
+0.08
+0.56%
 
EUM
22.73
+0.08
+0.35%
 
FANG
101.65
+1.24
+1.23%
 
HAIN
34.88
+0.27
+0.78%
 
HDB
71.49
-0.03
-0.04%
 
INCY
134.02
+2.81
+2.14%
 
IONS
46.9
+2.31
+5.18%
 
ITUB
12.92
+0.11
+0.86%
 
LNG
48.91
+1.45
+3.06%
 
MGM
26.47
+0.08
+0.30%
 
MPC
50.76
+0.73
+1.46%
 
OGXI
0.565
-0.025
-4.2203%
 
RSPP
40.97
+1.08
+2.71%
 
SFTBY
37.48
-0.63
-1.65%
 
STO
17.6
+0.19
+1.09%
 
SYNA
55.82
+0.27
+0.49%
 
TRGP
55.91
-0.47
-0.83%
 
V
88
-0.43
-0.49%
 
VMC
120.6
+2.78
+2.36%
 
XYL
48.95
+1.05
+2.19%
 
NASDAQ
5861.9
+16.59
+0.28%
 
S&P500
2369.75
+2.41
+0.10%
 
NYSE
11558.35
+17.06
+0.15%
 
ACAD
39.85
+0.97
+2.49%
 
AGN
246.25
+0.88
+0.36%
 
ALV
105.02
+0.41
+0.39%
 
BABA
103.6
+0.65
+0.63%
 
BMY
56.56
+0.12
+0.21%
 
DHR
86.13
+0.05
+0.06%
 
DXJR
13.62
+0.08
+0.56%
 
EUM
22.73
+0.08
+0.35%
 
FANG
101.65
+1.24
+1.23%
 
HAIN
34.88
+0.27
+0.78%
 
HDB
71.49
-0.03
-0.04%
 
INCY
134.02
+2.81
+2.14%
 
IONS
46.9
+2.31
+5.18%
 
ITUB
12.92
+0.11
+0.86%
 
LNG
48.91
+1.45
+3.06%
 
MGM
26.47
+0.08
+0.30%
 
MPC
50.76
+0.73
+1.46%
 
OGXI
0.565
-0.025
-4.2203%
 
RSPP
40.97
+1.08
+2.71%
 
SFTBY
37.48
-0.63
-1.65%
 
STO
17.6
+0.19
+1.09%
 
SYNA
55.82
+0.27
+0.49%
 
TRGP
55.91
-0.47
-0.83%
 
V
88
-0.43
-0.49%
 
VMC
120.6
+2.78
+2.36%
 
XYL
48.95
+1.05
+2.19%
 

Jubak Top 50 Portfolio

The 50 Best Stocks in the World

Jubak Top 50 Performance for 2016:
21.5%

NASDAQ
5861.9
+16.59
+0.28%
 
S&P500
2369.75
+2.41
+0.10%
 
NYSE
11558.35
+17.06
+0.15%
 
ALB
92.46
-0.47
-0.51%
 
TCEHY
27.075
-0.03
-0.111%
 
AGN
246.25
+0.88
+0.36%
 
AAPL
136.93
+0.27
+0.20%
 
FB
136.41
+0.97
+0.72%
 
AMZN
848.64
+3.4
+0.40%
 
BABA
103.6
+0.65
+0.63%
 
CHK
5.62
-0.04
-0.71%
 
EBAY
34.28
+0.22
+0.65%
 
LNG
48.91
+1.45
+3.06%
 
CMI
149.91
-0.03
-0.02%
 
MIDD
139
-0.05
-0.04%
 
PXD
186.72
+1.36
+0.73%
 
AUY
2.74
-0.05
-1.79%
 
DD
79.23
-0.58
-0.73%
 
FLR
56.16
+1.07
+1.94%
 
CNI
71.03
+0.56
+0.79%
 
SPWR
8.98
+0.09
+1.01%
 
GE
29.94
-0.25
-0.83%
 
BHP
38.6
+0.63
+1.66%
 
BG
81.4
+0.35
+0.43%
 
CX
8.81
+0.27
+3.16%
 
CSCO
34.26
-0.06
-0.17%
 
COH
38.71
+0.69
+1.81%
 
GLW
27.65
-0.08
-0.29%
 
DE
109.51
+0.89
+0.82%
 
ENB
41.59
+0.25
+0.60%
 
XOM
81.54
+0.46
+0.57%
 
FLS
47.94
+0.22
+0.46%
 
FCX
13.27
+0.02
+0.15%
 
BGC
17.1
+0.75
+4.59%
 
GOOG
829.28
+0.64
+0.08%
 
HDB
71.49
-0.03
-0.04%
 
INFY
15.21
0.00
0.00%
 
ITUB
12.92
+0.11
+0.86%
 
JCI
42.24
+0.42
+1.00%
 
LFL
10.07
0.00
0.00%
 
LUX
52.75
+0.35
+0.67%
 
MON
113.59
+0.63
+0.56%
 
PEP
109.27
-0.56
-0.51%
 
POT
17.83
-0.04
-0.22%
 
RYN
28.94
+0.26
+0.91%
 
SLB
81.06
+0.91
+1.14%
 
TS
33.48
+0.5
+1.52%
 
VALE
10.61
+0.09
+0.86%
 
NASDAQ
5861.9
+16.59
+0.28%
 
S&P500
2369.75
+2.41
+0.10%
 
NYSE
11558.35
+17.06
+0.15%
 
ALB
92.46
-0.47
-0.51%
 
TCEHY
27.075
-0.03
-0.111%
 
AGN
246.25
+0.88
+0.36%
 
AAPL
136.93
+0.27
+0.20%
 
FB
136.41
+0.97
+0.72%
 
AMZN
848.64
+3.4
+0.40%
 
BABA
103.6
+0.65
+0.63%
 
CHK
5.62
-0.04
-0.71%
 
EBAY
34.28
+0.22
+0.65%
 
LNG
48.91
+1.45
+3.06%
 
CMI
149.91
-0.03
-0.02%
 
MIDD
139
-0.05
-0.04%
 
PXD
186.72
+1.36
+0.73%
 
AUY
2.74
-0.05
-1.79%
 
DD
79.23
-0.58
-0.73%
 
FLR
56.16
+1.07
+1.94%
 
CNI
71.03
+0.56
+0.79%
 
SPWR
8.98
+0.09
+1.01%
 
GE
29.94
-0.25
-0.83%
 
BHP
38.6
+0.63
+1.66%
 
BG
81.4
+0.35
+0.43%
 
CX
8.81
+0.27
+3.16%
 
CSCO
34.26
-0.06
-0.17%
 
COH
38.71
+0.69
+1.81%
 
GLW
27.65
-0.08
-0.29%
 
DE
109.51
+0.89
+0.82%
 
ENB
41.59
+0.25
+0.60%
 
XOM
81.54
+0.46
+0.57%
 
FLS
47.94
+0.22
+0.46%
 
FCX
13.27
+0.02
+0.15%
 
BGC
17.1
+0.75
+4.59%
 
GOOG
829.28
+0.64
+0.08%
 
HDB
71.49
-0.03
-0.04%
 
INFY
15.21
0.00
0.00%
 
ITUB
12.92
+0.11
+0.86%
 
JCI
42.24
+0.42
+1.00%
 
LFL
10.07
0.00
0.00%
 
LUX
52.75
+0.35
+0.67%
 
MON
113.59
+0.63
+0.56%
 
PEP
109.27
-0.56
-0.51%
 
POT
17.83
-0.04
-0.22%
 
RYN
28.94
+0.26
+0.91%
 
SLB
81.06
+0.91
+1.14%
 
TS
33.48
+0.5
+1.52%
 
VALE
10.61
+0.09
+0.86%
 

Dividend Income Portfolio

Stocks that Pay You

Dividend Income Performance for 2016:
26.8%

NASDAQ
5861.9
+16.59
+0.28%
 
S&P500
2369.75
+2.41
+0.10%
 
NYSE
11558.35
+17.06
+0.15%
 
COH
38.71
+0.69
+1.81%
 
GE
29.94
-0.25
-0.83%
 
KMI
21.4
+0.16
+0.75%
 
OKS
51.8
+0.27
+0.52%
 
PFXF
20.11
+0.01
+0.05%
 
QCOM
56.73
+0.04
+0.07%
 
SDRL
2.04
+0.06
+3.03%
 
TRGP
55.91
-0.47
-0.83%
 
VZ
49.94
-0.66
-1.30%
 
WBK
25.99
-0.11
-0.42%
 
WES
62.21
-0.58
-0.92%
 
XOM
81.54
+0.46
+0.57%
 
NASDAQ
5861.9
+16.59
+0.28%
 
S&P500
2369.75
+2.41
+0.10%
 
NYSE
11558.35
+17.06
+0.15%
 
COH
38.71
+0.69
+1.81%
 
GE
29.94
-0.25
-0.83%
 
KMI
21.4
+0.16
+0.75%
 
OKS
51.8
+0.27
+0.52%
 
PFXF
20.11
+0.01
+0.05%
 
QCOM
56.73
+0.04
+0.07%
 
SDRL
2.04
+0.06
+3.03%
 
TRGP
55.91
-0.47
-0.83%
 
VZ
49.94
-0.66
-1.30%
 
WBK
25.99
-0.11
-0.42%
 
WES
62.21
-0.58
-0.92%
 
XOM
81.54
+0.46
+0.57%
 
Best in Business Award

Archives:

Follow me on Twitter:

Merck writes off $2.9 billion it spent on hepatitis C drug purchased in 2014; here’s who to watch in the biotech sector after this news

Merck writes off $2.9 billion it spent on hepatitis C drug purchased in 2014; here’s who to watch in the biotech sector after this news

Merck (MRK) has announced that it will take a $2.9 billion charge (or $1.9 billion after taxes) and restate its fourth quarter and full year 2016 earnings (announced on February 3) to write down most of its 2014 purchase of Idenix Pharmaceuticals and its hepatitis C drug candidate. This isn’t good news for Merck. Before the charge Merck had reported fourth-quarter earnings of 89 cents a share, below Wall Street projections and below the 93 cents a share the company earned in the fourth quarter of 2015. For 2017 the company is now projecting revenue in the range of $38.6 billion to $40.1 billion. That’s essentially flat with 2016 revenue. But the ripples from the announcement are likely to spread through the drug and biotech sectors.

read more

So which is it? Is China a currency manipulator or not? Trump administration can’t make up its mind

On Thursday, February 23, President Donald Trump told Reuters that China is guilty of manipulating its currency to lower the price of the yuan in order to make its exports cheaper.“I think they’re grand champions at manipulation of currency. So I haven’t held back. We’ll see what happens,” Trump said. During the campaign Trump had promised to brand China a currency manipulator on his first day in office. Those comments were reported just hours after the new Treasury Secretary Steven Mnuchin said the U.S. Treasury had no immediate plans to label China a currency manipulator

read more
Incyte is on the way to becoming a complete drug company–or an expensive acquisition candidate

Incyte is on the way to becoming a complete drug company–or an expensive acquisition candidate

Usually with a biotech stock you trade the present for the future: no revenue now but the promise of big revenue to come. Incyte’s (INCY) most recent quarter, reported on February 14, doesn’t require that trade off. Which means investors should be asking a different set of questions about the future of the company. For the quarter revenue climbed to $326.5 million, up 33.9% year over year.

read more
In minutes released today Fed says “Fairly soon” but probably not March for next interest rate increase

In minutes released today Fed says “Fairly soon” but probably not March for next interest rate increase

The Federal Reserve’s minutes from its January 31 to February 1 meeting show the odds still slightly tilted to waiting a bit longer before raising interest rates. The worries that are pushing the Fed toward some delay include uncertainty over the effects of a stronger dollar and the dimensions of any fiscal stimulus plan coming from the Trump administration. Waiting until after the March 15 meeting of the Federal Open Market Committee to the May 3 or June 14 meetings would enable the U.S. central bank to clarify those worries.

read more
Copper headed higher? For Freeport McMoRan Copper and Gold this may not end badly but it won’t end soon

Copper headed higher? For Freeport McMoRan Copper and Gold this may not end badly but it won’t end soon

With the world’s largest copper mine at Escondida in Chile out on strike, the fight between Freeport McMoRan Copper and Gold (FCX) and Indonesia is a big, big deal. Copper has already climbed above $6,000 a metric ton and the metal is likely to head higher the longer the conflict drags on. On Monday, February 20, copper for March delivery climbed 1.6% to $6,066 a metric ton. On Tuesday, February 21, copper retreated 0.36%. The root cause is a demand by the Indonesian government that Freeport follow newly written rules at the company’s huge Grasberg mine

read more

Jim’s Daily Email Alerts:

Every post from Jubak Picks straight to your mailbox. And they're free!

Get Even More Jim!

  • • More profiles of hot (and cold) sectors
  • • More strategies for profiting from volatility
  • • More about macro trends driving the market
  • • More on where the market is heading – short-, medium- and long-term – including a Saturday Night Quarterback look at the week ahead!

Subscribe now for a year for just $199

Stock Trader's Almanac 2016 Best Investing Book

Topics:

  • Breaking News
  • Buy
  • Dividend Income Portfolio
  • Important Stuff
  • Jubak Picks Portfolio
  • Jubak Top 50 Portfolio
  • Leading Indicators
  • Recent Buys
  • Sell
  • Update
  • Stuff Jim Recommends
  • Volatility
  • You May Have Missed

Keyword Tags

All Keyword Tags

Tag Cloud Widget powered by WP Tutor